Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | OGA | O60502 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | PANK3 | Q9H999 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | BPTF | Q12830 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037518 | 0.83 | BPTF (0.56) | MAP4K4OGAALDH1A1SMOMAPT | |
| SCHEMBL20037531 | 0.82 | PANK3 (0.46) | OGAPANK3 | |
| SCHEMBL3827722 | 0.81 | KDM4E (0.43) | OGASMN1; SMN2PANK3ALDH1A1LMNA | |
| SCHEMBL20249439 | 0.80 | TRPV1 (0.49) | MAP4K4TSHRSMN1; SMN2METPANK3 | |
| SCHEMBL20255261 | 0.79 | L3MBTL1 (0.49) | OGATSHRSMN1; SMN2PANK3ALDH1A1 | |
| SCHEMBL20255262 | 0.76 | OGA (0.58) | OGAALDH1A1MAPT | |
| SCHEMBL20037669 | 0.76 | PANK3 (0.48) | PANK3ALDH1A1SMOMAPT | |
| SCHEMBL16427561 | 0.76 | GPR119 (0.57) | MAP4K4ALDH1A1LMNAMAPT | |
| SCHEMBL3828458 | 0.74 | ALDH1A1 (0.52) | TSHRSMN1; SMN2METALDH1A1LMNA | |
| SCHEMBL11527143 | 0.74 | HTR3A (0.56) | OGAALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | MAP4K4 191/4885OGA 4627/4885TSHR 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.